CBP AI Flags Transshipped Goods Before Customs Clears Them, Closing Post-Audit Loophole

Meta said on Aug. 12, 2026 it removed 756,000 Facebook and Instagram accounts of Australians under 16 during the prior seven months, citing compliance with Australia’s social media age ban. Meta attributed detection to AI and post-sign-up behavioral and content signals, not sign-up age verification. Australia’s eSafety Commissioner reported 81.5% of under-16s still used restricted platforms three months after the ban. A Senate review may double penalties to A$99m.

Maharashtra’s Food and Drug Administration suspended licenses for four Domino’s outlets after reports of grease residue and insect infestations, and suspended one Pizza Hut store for products lacking expiry dates, according to a Reuters-shared FDA note. Jubilant FoodWorks and Sapphire Foods did not comment. Regulators have also increased hygiene and labeling enforcement in India.

Bristol Myers Squibb said the FDA granted accelerated approval for Zenbexus (a CELMoD) in multiple myeloma, for patients previously treated with a proteasome inhibitor and an immunomodulatory agent. Approval followed Phase III EXCALIBER-RRMM results versus daratumumab, bortezomib and dexamethasone, with MRD-negative complete response at 41% vs 21% at 16 months. Safety included 4.9% fatal adverse reactions.

North Carolina Attorney General Jeff Jackson accused Duke Energy of false sworn testimony about a proposed rate increase. At a state commission hearing, Duke said residential hikes would average 6.8%, but Jackson’s office calculated a 9.3% increase. Jackson says he will not sign the settlement. Duke denies misleading regulators. Environmental groups also urge lower profit targets and more renewables.

EU officials agreed to study an experimental Lyme disease vaccine, according to Pfizer and Valneva. The firms said trials showed about 70% efficacy in ages 5+ and that the European Medicines Agency accepted an approval application for PF-07307405. Valneva shares rose about 16% in Paris trading.

The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma after at least one prior therapy line. Full approval depends on confirmatory trials. In Phase III Excaliber-RRMM, MRD-negative complete response was 41% vs 21% at median 16 months.